Inozyme Pharma, Inc. (INZY)
Stock Price:
$26.97 USD
0.74 (2.80%)
Updated November 30, 2:27 PM EST - Market open
Key Info
| Market Cap |
630.25M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
23.37M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 30 |
| Last Price |
$26.97 |
| Previous Close |
$26.23 |
| Change ($) |
0.74 |
| Change (%) |
2.80% |
| Day's Open |
26.08 |
| Day's Range |
25.88 - 26.97 |
| Day's Volume |
8,453 |
| 52-Week Range |
17.54 - 30.20 |
More Stats
| Market Cap |
630.25M |
| Enterprise Value |
471.66M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
23.37M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
583,789 |
| Short Ratio |
13.29 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.65 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
158.59M |
| Net Cash / Share |
6.79 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$36.67*
(35.99% upside)
Low
33.0
Current: $26.97
High
40.0
Target: 36.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -20.81 | -11.59 |
| Net Income | -19.72 | -6.96 |
| Shares Outstanding | 1.18 | 1.05 |
| Earnings Per Share | -16.67 | -6.63 |
| Operating Cash Flow | -18.81 | -9.44 |
| Capital Expenditures | -0.14 | -0.26 |
| Free Cash Flow | -18.95 | -9.70 |
| Cash & Equivalents | 47.26 | 43.16 |
| Net Cash / Debt | 47.26 | 43.16 |
| Assets | 47.94 | 43.54 |
| Liabilities | 3.24 | 57.42 |
| Book Value | -33.22 | -13.88 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Inozyme Pharma, Inc. |
| Country |
United States |
| CEO |
Axel Bolte |
Stock Information
| Ticker Symbol |
INZY |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: INZY |
| IPO Date |
July 24, 2020 |
Description
Inozyme Pharma, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.